Imodium Advanced may be available in the countries listed below.
Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Imodium Advanced in the following countries:
Simeticone is reported as an ingredient of Imodium Advanced in the following countries:
International Drug Name Search
Chlokinan may be available in the countries listed below.
Chlormadinone 17α-acetate (a derivative of Chlormadinone) is reported as an ingredient of Chlokinan in the following countries:
International Drug Name Search
Perycit may be available in the countries listed below.
Niceritrol is reported as an ingredient of Perycit in the following countries:
International Drug Name Search
Ceftazidime Arrow Enfants et Nourrissons may be available in the countries listed below.
Ceftazidime pentahydrate (a derivative of Ceftazidime) is reported as an ingredient of Ceftazidime Arrow Enfants et Nourrissons in the following countries:
International Drug Name Search
Dexamethasone Kela may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Dexamethasone is reported as an ingredient of Dexamethasone Kela in the following countries:
International Drug Name Search
Amirel may be available in the countries listed below.
Mirtazapine is reported as an ingredient of Amirel in the following countries:
International Drug Name Search
Cefanil may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ceftiofur hydrochloride (a derivative of Ceftiofur) is reported as an ingredient of Cefanil in the following countries:
International Drug Name Search
Paroxetin Ranbaxy may be available in the countries listed below.
Paroxetine hydrochloride (a derivative of Paroxetine) is reported as an ingredient of Paroxetin Ranbaxy in the following countries:
International Drug Name Search
Carvedilol Cinfamed may be available in the countries listed below.
Carvedilol is reported as an ingredient of Carvedilol Cinfamed in the following countries:
International Drug Name Search
Ibuprofeno Durban may be available in the countries listed below.
Ibuprofen is reported as an ingredient of Ibuprofeno Durban in the following countries:
International Drug Name Search
Zinpro may be available in the countries listed below.
Zinc Sulfate is reported as an ingredient of Zinpro in the following countries:
International Drug Name Search
Leucomycin may be available in the countries listed below.
Kitasamycin tartrate (a derivative of Kitasamycin) is reported as an ingredient of Leucomycin in the following countries:
International Drug Name Search
UK matches:
Rec.INN
0015500-66-0
C35-H60-Br2-N2-O4
732
Muscle relaxant, peripherally acting
Piperidinium, 1,1'-[(2ß,3α,5α,16ß,17ß)-3,17-bis(acetyloxy)androstane-2,16-diyl]bis[1-methyl-, dibromide
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| SPC | Summary of Product Characteristics (UK) |
| USAN | United States Adopted Name |
Carvedilol Interpharm may be available in the countries listed below.
Carvedilol is reported as an ingredient of Carvedilol Interpharm in the following countries:
International Drug Name Search
Casacine may be available in the countries listed below.
Capsaicin is reported as an ingredient of Casacine in the following countries:
International Drug Name Search
Tuzodin may be available in the countries listed below.
Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Tuzodin in the following countries:
International Drug Name Search
Anecortave Acetate may be available in the countries listed below.
Anecortave Acetate (JAN, USAN) is also known as Anecortave (Rec.INN)
International Drug Name Search
Glossary
| JAN | Japanese Accepted Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Chiyoban may be available in the countries listed below.
Disopyramide is reported as an ingredient of Chiyoban in the following countries:
International Drug Name Search
Schwarz Isosorbide Mononitrate may be available in the countries listed below.
Isosorbide Mononitrate is reported as an ingredient of Schwarz Isosorbide Mononitrate in the following countries:
International Drug Name Search
In the US, Canesten 3 is a member of the following drug classes: topical antifungals, vaginal anti-infectives and is used to treat Vaginal Yeast Infection.
Clotrimazole is reported as an ingredient of Canesten 3 in the following countries:
International Drug Name Search
Ebenol may be available in the countries listed below.
Hydrocortisone is reported as an ingredient of Ebenol in the following countries:
Hydrocortisone 21-acetate (a derivative of Hydrocortisone) is reported as an ingredient of Ebenol in the following countries:
International Drug Name Search
Ceperatam may be available in the countries listed below.
Cefoperazone sodium salt (a derivative of Cefoperazone) is reported as an ingredient of Ceperatam in the following countries:
International Drug Name Search
Calmurid may be available in the countries listed below.
UK matches:
Hydrocortisone is reported as an ingredient of Calmurid in the following countries:
Lactic Acid is reported as an ingredient of Calmurid in the following countries:
Urea is reported as an ingredient of Calmurid in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Floxobid may be available in the countries listed below.
Ciprofloxacin is reported as an ingredient of Floxobid in the following countries:
International Drug Name Search
Dispercarpine may be available in the countries listed below.
Pilocarpine hydrochloride (a derivative of Pilocarpine) is reported as an ingredient of Dispercarpine in the following countries:
International Drug Name Search
Morphine HCL may be available in the countries listed below.
Morphine hydrochloride (a derivative of Morphine) is reported as an ingredient of Morphine HCL in the following countries:
International Drug Name Search
Fenofix may be available in the countries listed below.
Fenofibrate is reported as an ingredient of Fenofix in the following countries:
International Drug Name Search
Gran may be available in the countries listed below.
Filgrastim is reported as an ingredient of Gran in the following countries:
International Drug Name Search
Pankreatin Mikro-ratiopharm may be available in the countries listed below.
Pancreatin is reported as an ingredient of Pankreatin Mikro-ratiopharm in the following countries:
International Drug Name Search
Sulmetrim may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Sulfamethoxazole is reported as an ingredient of Sulmetrim in the following countries:
Trimethoprim is reported as an ingredient of Sulmetrim in the following countries:
International Drug Name Search
Gasmotin may be available in the countries listed below.
Mosapride citrate dihydrate (a derivative of Mosapride) is reported as an ingredient of Gasmotin in the following countries:
International Drug Name Search
Cotson may be available in the countries listed below.
Hydrocortisone 21-(sodium succinate) (a derivative of Hydrocortisone) is reported as an ingredient of Cotson in the following countries:
International Drug Name Search
Advantan may be available in the countries listed below.
Methylprednisolone is reported as an ingredient of Advantan in the following countries:
Methylprednisolone 21-acetate (a derivative of Methylprednisolone) is reported as an ingredient of Advantan in the following countries:
Methylprednisolone aceponate (a derivative of Methylprednisolone) is reported as an ingredient of Advantan in the following countries:
International Drug Name Search
Cimegast may be available in the countries listed below.
Cimetidine is reported as an ingredient of Cimegast in the following countries:
International Drug Name Search
Cimetidine A may be available in the countries listed below.
Cimetidine is reported as an ingredient of Cimetidine A in the following countries:
International Drug Name Search
Generic Name: riboflavin (vitamin B2) (RYE bow flay vin)
Brand Names: Vitamin B2
Riboflavin is vitamin B2. Vitamins are naturally occurring substances necessary for many processes in the body. Riboflavin is important in the maintenance of many tissues of the body.
Riboflavin is used to prevent and to treat deficiencies of riboflavin.
Riboflavin may also be used for other purposes not listed in this medication guide.
Use riboflavin as directed on the label, or as your healthcare provider has prescribed. Do not use this product in larger amounts or for longer than recommended.
Before taking riboflavin, talk to your doctor, pharmacist, or health care professional if you have any other medical conditions, allergies, or if you take other medicines or other herbal/health supplements.
Use riboflavin as directed on the label, or as your healthcare provider has prescribed. Do not use this product in larger amounts or for longer than recommended.
Skip the missed dose if it is almost time for your next scheduled dose. Do not use extra medicine to make up the missed dose.
Follow your healthcare provider's instructions about any restrictions on food, beverages, or activity.
Riboflavin may cause your urine to become a yellow-orange color. This effect is harmless.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
There may be other drugs that can interact with riboflavin. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Stedon may be available in the countries listed below.
Diazepam is reported as an ingredient of Stedon in the following countries:
International Drug Name Search
Mucoserum L may be available in the countries listed below.
Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Mucoserum L in the following countries:
International Drug Name Search
In the US, Lusedra (fospropofol systemic) is a member of the drug class general anesthetics and is used to treat Anesthesia and Sedation.
US matches:
Fospropofol disodium (a derivative of Fospropofol) is reported as an ingredient of Lusedra in the following countries:
International Drug Name Search
Paroxetina Mepha may be available in the countries listed below.
Paroxetine hydrochloride (a derivative of Paroxetine) is reported as an ingredient of Paroxetina Mepha in the following countries:
International Drug Name Search
Cefuroxime-1A may be available in the countries listed below.
Cefuroxime is reported as an ingredient of Cefuroxime-1A in the following countries:
International Drug Name Search
Mucospire may be available in the countries listed below.
Acetylcysteine is reported as an ingredient of Mucospire in the following countries:
International Drug Name Search
New Kenacomb may be available in the countries listed below.
Nystatin is reported as an ingredient of New Kenacomb in the following countries:
Triamcinolone 16α,17α-acetonide (a derivative of Triamcinolone) is reported as an ingredient of New Kenacomb in the following countries:
International Drug Name Search
Liqui-Char-Vet may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Charcoal, Activated is reported as an ingredient of Liqui-Char-Vet in the following countries:
International Drug Name Search
In the US, Ala-Scalp (hydrocortisone topical) is a member of the drug class topical steroids and is used to treat Dermatitis, Eczema, Gingivitis, Pruritus, Psoriasis, Seborrheic Dermatitis and Skin Rash.
US matches:
Hydrocortisone is reported as an ingredient of Ala-Scalp in the following countries:
International Drug Name Search
Bisoprolol Hexpharm may be available in the countries listed below.
Bisoprolol is reported as an ingredient of Bisoprolol Hexpharm in the following countries:
International Drug Name Search
Acetilcisteina Cinfa may be available in the countries listed below.
Acetylcysteine is reported as an ingredient of Acetilcisteina Cinfa in the following countries:
International Drug Name Search
Pretir may be available in the countries listed below.
Azithromycin is reported as an ingredient of Pretir in the following countries:
International Drug Name Search
There are currently no drugs listed for "Cerebellar Degeneration". See Neurological Disorders.
Definition of Cerebellar Degeneration:
Cerebellar degeneration is a process in which neurons in the cerebellum - the area of the brain that controls coordination and balance - deteriorate and die. Diseases that cause cerebellar degeneration can also involve other areas of the central nervous system,including the spinal cord, medulla oblongata, cerebral cortex, and brain stem. Cerebellar degeneration may be the result of inherited genetic mutations that alter the normal production of specific proteins that are necessary for the survival of neurons.Ciprofibrate Ratiopharm may be available in the countries listed below.
Ciprofibrate is reported as an ingredient of Ciprofibrate Ratiopharm in the following countries:
International Drug Name Search
Pantoprazole Ranbaxy may be available in the countries listed below.
Pantoprazole is reported as an ingredient of Pantoprazole Ranbaxy in the following countries:
International Drug Name Search
N-Propranolol may be available in the countries listed below.
Propranolol is reported as an ingredient of N-Propranolol in the following countries:
International Drug Name Search
Lactulose Copyfarm may be available in the countries listed below.
Lactulose is reported as an ingredient of Lactulose Copyfarm in the following countries:
International Drug Name Search
Formo-Cibazol may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Formosulfathiazole is reported as an ingredient of Formo-Cibazol in the following countries:
International Drug Name Search
Risperidon Hennig may be available in the countries listed below.
Risperidone is reported as an ingredient of Risperidon Hennig in the following countries:
International Drug Name Search
Aarane may be available in the countries listed below.
Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Aarane in the following countries:
Reproterol hydrochloride (a derivative of Reproterol) is reported as an ingredient of Aarane in the following countries:
International Drug Name Search
Meglumine Iotroxate may be available in the countries listed below.
Meglumine Iotroxate (BANM) is also known as Iotroxic Acid (Rec.INN)
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Bioparox may be available in the countries listed below.
Fusafungine is reported as an ingredient of Bioparox in the following countries:
International Drug Name Search
Ocefazine may be available in the countries listed below.
Oxaprozin is reported as an ingredient of Ocefazine in the following countries:
International Drug Name Search
Cilest 28 may be available in the countries listed below.
Ethinylestradiol is reported as an ingredient of Cilest 28 in the following countries:
Norgestimate is reported as an ingredient of Cilest 28 in the following countries:
International Drug Name Search
Pinnel may be available in the countries listed below.
Metamizole sodium anhydrous (a derivative of Metamizole) is reported as an ingredient of Pinnel in the following countries:
International Drug Name Search
Fabotensil may be available in the countries listed below.
Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Fabotensil in the following countries:
International Drug Name Search
Carve TAD may be available in the countries listed below.
Carvedilol is reported as an ingredient of Carve TAD in the following countries:
International Drug Name Search
Calperos may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Calperos in the following countries:
International Drug Name Search
Disopa may be available in the countries listed below.
Phthalaldehyde, o- is reported as an ingredient of Disopa in the following countries:
International Drug Name Search
Ascobex may be available in the countries listed below.
Ascorbic Acid is reported as an ingredient of Ascobex in the following countries:
International Drug Name Search
Epdantoin may be available in the countries listed below.
Phenytoin sodium salt (a derivative of Phenytoin) is reported as an ingredient of Epdantoin in the following countries:
International Drug Name Search
Cefadroxil Mylan may be available in the countries listed below.
Cefadroxil monohydrate (a derivative of Cefadroxil) is reported as an ingredient of Cefadroxil Mylan in the following countries:
International Drug Name Search
Vectin may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ivermectin is reported as an ingredient of Vectin in the following countries:
International Drug Name Search
Tinidazolum may be available in the countries listed below.
Tinidazole is reported as an ingredient of Tinidazolum in the following countries:
International Drug Name Search
Halosten may be available in the countries listed below.
Haloperidol is reported as an ingredient of Halosten in the following countries:
International Drug Name Search
Corbeta may be available in the countries listed below.
Propranolol hydrochloride (a derivative of Propranolol) is reported as an ingredient of Corbeta in the following countries:
International Drug Name Search
Vastarel MR may be available in the countries listed below.
Trimetazidine dihydrochloride (a derivative of Trimetazidine) is reported as an ingredient of Vastarel MR in the following countries:
International Drug Name Search
Xylometazolin ICN Polfa may be available in the countries listed below.
Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of Xylometazolin ICN Polfa in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Parlodel (bromocriptine systemic) is a member of the following drug classes: dopaminergic antiparkinsonism agents, prolactin inhibitors and is used to treat Acromegaly, Hyperprolactinemia and Parkinson's Disease.
US matches:
UK matches:
Bromocriptine is reported as an ingredient of Parlodel in the following countries:
Bromocriptine mesilate (a derivative of Bromocriptine) is reported as an ingredient of Parlodel in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
In some countries, this medicine may only be approved for veterinary use.
Triamcinolone 16α,17α-acetonide (a derivative of Triamcinolone) is reported as an ingredient of Vetalog in the following countries:
International Drug Name Search
In the US, Orthovisc (hyaluronan systemic) is a member of the drug class viscosupplementation agents and is used to treat Osteoarthritis.
US matches:
Hyaluronic Acid sodium salt (a derivative of Hyaluronic Acid) is reported as an ingredient of Orthovisc in the following countries:
International Drug Name Search
Pamidronate de Sodium Mylan may be available in the countries listed below.
Pamidronic Acid disodium salt (a derivative of Pamidronic Acid) is reported as an ingredient of Pamidronate de Sodium Mylan in the following countries:
International Drug Name Search
Sertralina Hexal may be available in the countries listed below.
Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Sertralina Hexal in the following countries:
International Drug Name Search
Lotrix may be available in the countries listed below.
Permethrin is reported as an ingredient of Lotrix in the following countries:
International Drug Name Search
Capsicin Crema may be available in the countries listed below.
Capsaicin is reported as an ingredient of Capsicin Crema in the following countries:
International Drug Name Search
Cepraz may be available in the countries listed below.
Cefoperazone sodium salt (a derivative of Cefoperazone) is reported as an ingredient of Cepraz in the following countries:
International Drug Name Search
Midazolam Panpharma may be available in the countries listed below.
Midazolam is reported as an ingredient of Midazolam Panpharma in the following countries:
International Drug Name Search
Asucrose may be available in the countries listed below.
Acarbose is reported as an ingredient of Asucrose in the following countries:
International Drug Name Search
Lisomucil may be available in the countries listed below.
Carbocisteine is reported as an ingredient of Lisomucil in the following countries:
Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Lisomucil in the following countries:
International Drug Name Search
Ampicat may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Ampicat in the following countries:
International Drug Name Search
Glimepiride Sanwin may be available in the countries listed below.
Glimepiride is reported as an ingredient of Glimepiride Sanwin in the following countries:
International Drug Name Search
Scholl Athlete's Foot Powder may be available in the countries listed below.
UK matches:
Tolnaftate is reported as an ingredient of Scholl Athlete's Foot Powder in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Colwen may be available in the countries listed below.
Valethamate Bromide is reported as an ingredient of Colwen in the following countries:
International Drug Name Search
Trim may be available in the countries listed below.
Trimebutine maleate (a derivative of Trimebutine) is reported as an ingredient of Trim in the following countries:
International Drug Name Search
Diclabeta may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclabeta in the following countries:
International Drug Name Search
Formalin may be available in the countries listed below.
Formalin (JAN) is known as Formaldehyde in the US.
International Drug Name Search
Glossary
| JAN | Japanese Accepted Name |
Fentanilo Acostlabs may be available in the countries listed below.
Fentanyl is reported as an ingredient of Fentanilo Acostlabs in the following countries:
International Drug Name Search
Generic Name: Oxacillin Sodium
Class: Penicillinase-resistant Penicillins
Chemical Name: [2S - (2α,5α,6β)] - 3,3 - Dimethyl - 6 - [[(5 - methyl - 3 - phenyl - 4 - isoxazolyl)carbonyl]amino] - 7 - oxo - 4 - thia - 1 - azabicyclo[3.2.0]heptane - 2 - carboxylic acid monosodium salt monohydrate
CAS Number: 7240-38-2
Antibacterial; β-lactam antibiotic; isoxazolyl penicillin classified as a penicillinase-resistant penicillin.1 4 5 9 46 70
Treatment of infections caused by, or suspected of being caused by, susceptible penicillinase-producing staphylococci,1 6 47 66 70 71 including respiratory tract, skin and skin structure, bone and joint, and urinary tract infections and meningitis or bacteremia.a A drug of choice for these infections.a
Treatment of native valve or prosthetic valve endocarditis caused by susceptible staphylococci.50 69 A drug of choice;50 69 used with or without gentamicin for native valve endocarditis and used in conjunction with rifampin and gentamicin for prosthetic valve endocarditis.50 69
If used empirically, consider whether staphylococci resistant to penicillinase-resistant penicillins (oxacillin-resistant [methicillin-resistant] staphylococci) are prevalent in the hospital or community.a (See Staphylococci Resistant to Penicillinase-resistant Penicillins under Cautions.)
Has been used for perioperative prophylaxis† in patients undergoing neurosurgery or cardiovascular or orthopedic surgery associated with high risk of staphylococcal infections.a Not considered a drug of choice.a
Administer by IV injection or infusion or by IM injection.1
To reduce risk of thrombophlebitis and other adverse local reactions associated with IV administration (particularly in geriatric patients), administer slowly and take care to avoid extravasation.1 a
Reconstitute vials containing 1 or 2 g of oxacillin by adding 10 or 20 mL, respectively, of sterile water for injection or 0.45 or 0.9% sodium chloride injection to provide solutions containing approximately 100 mg/mL.1
Inject appropriate dose slowly over a period of about 10 minutes.1
Reconstitute vials containing 1 or 2 g of oxacillin by adding 10 or 20 mL, respectively, of sterile water for injection or 0.45 or 0.9% sodium chloride injection to provide a solution containing approximately 100 mg/mL.1 Reconstituted solution should then be further diluted with a compatible IV solution (see Solution Compatibility under Stability) to a concentration of 0.5–40 mg/mL.1
Alternatively, ADD-Vantage vials containing 1 or 2 g of the drug should be reconstituted according to the manufacturer’s directions.63
Reconstitute 10-g pharmacy bulk package with 93 mL of sterile water for injection or 0.9% sodium chloride injection to provide a solution containing 100 mg/mL.2 Pharmacy bulk packages of the drug are not intended for direct IV infusion; prior to administration, doses of the drug from the reconstituted pharmacy bulk package must be further diluted in a compatible IV infusion solution (see Solution Compatibility under Stability).2
Thaw the commercially available injection (frozen) at room temperature or in a refrigerator; do not force thaw by immersion in a water bath or by exposure to microwave radiation.64 A precipitate may have formed in the frozen injection, but should dissolve with little or no agitation after reaching room temperature.64 Discard thawed injection if an insoluble precipitate is present or if container seals or outlet ports are not intact.64 Additives should not be introduced into the injection.64 The injections should not be used in series connections with other plastic containers, since such use could result in air embolism from residual air being drawn from the primary container before administration of fluid from the secondary container is complete.64
The rate of IV infusion should be adjusted so that the total dose is administered before the drug is inactivated in the IV solution.1
Inject IM deeply into a large muscle (e.g., gluteus maximus) avoiding sciatic nerve injury.58
For IM injection, reconstitute vial containing 1 or 2 g of oxacillin by adding 5.7 or 11.4 mL, respectively, of sterile water for injection to provide solutions containing 167 mg/mL (250 mg/1.5 mL).1 Shake vial well until a clear solution is obtained.1
Available as oxacillin sodium; dosage expressed in terms of oxacillin.1
Duration of treatment depends on type and severity of infection and should be determined by clinical and bacteriologic response of the patient.1 58 64 For serious staphylococcal infections, duration usually is ≥1–2 weeks; more prolonged therapy is necessary for treatment of osteomyelitis or endocarditis.1 58 64 71
25 mg/kg daily recommended by manufacturer.1
Neonates <1 week of age: AAP recommends 25 mg/kg every 12 hours for those weighing <1.2 kg; 25–50 mg/kg every 12 hours for those weighing 1.2 to 2 kg; and 25–50 mg/kg every 8 hours for those weighing >2 kg.67 The higher dosages are recommended for meningitis.67
Neonates 1–4 weeks of age: AAP recommends 25 mg/kg every 12 hours for those weighing <1.2 kg; 25–50 mg/kg every 8 hours for those weighing 1.2 to 2 kg; and 25–50 mg/kg every 6 hours for those weighing >2 kg.67 The higher dosages are recommended for meningitis.67
Children weighing <40 kg: 50 mg/kg daily given in equally divided doses every 6 hours.1 58 64
Children weighing ≥40 kg: 250–500 mg every 4–6 hours.1 58 64
Children ≥1 month of age: AAP recommends 100–150 mg/kg daily in 4 divided doses.67
Children weighing <40 kg: 100–200 mg/kg daily given in equally divided doses every 4–6 hours.1 47 49 58 64 67 71
Children weighing ≥40 kg: 1 g every 4–6 hours.1 58 64
Children ≥1 month of age: AAP recommends 150–200 mg/kg daily in 4–6 divided doses.67
AHA recommends 200 mg/kg daily given in divided doses every 4–6 hours for 6 weeks (maximum 12 g daily).69
In addition, during the first 3–5 days of oxacillin therapy, IM or IV gentamicin (3 mg/kg daily given in divided doses every 8 hours; dosage adjusted to achieve peak serum gentamicin concentrations approximately 3 mcg/mL and trough concentrations <1 mcg/mL) may be given concomitantly if the causative organism is susceptible to the drug.69
AHA recommends 200 mg/kg daily given in divided doses every 4–6 hours for 6 weeks or longer (maximum 12 g daily).
Used in conjunction with oral rifampin (20 mg/kg daily given in divided doses every 8 hours for 6 weeks or longer) and IM or IV gentamicin (3 mg/kg daily given in divided doses every 8 hours during the first 2 weeks of oxacillin therapy; dosage adjusted to achieve peak serum gentamicin concentrations approximately 3 mcg/mL and trough concentrations <1 mcg/mL).69
250–500 mg every 4–6 hours.1 58 64
1 g every 4–6 hours.1 58 64
1.5–2 g every 4 hours.49
When used for treatment of acute or chronic osteomyelitis caused by susceptible penicillinase-producing staphylococci, parenteral therapy generally continued for 3–8 weeks;48 49 52 57 71 follow-up with an oral penicillinase-resistant penicillin (e.g., dicloxacillin) generally recommended.49 51 71 In treatment of acute osteomyelitis, a shorter course of parenteral penicillinase-resistant therapy (5–28 days) followed by 3–6 weeks of oral penicillinase-resistant penicillin therapy also has been effective.49 51 52 57
AHA recommends 2 g every 4 hours for 4–6 weeks.50
Although benefits of concomitant aminoglycosides have not been clearly established, AHA states that IM or IV gentamicin (1 mg/kg every 8 hours) may be given concomitantly during the first 3–5 days of oxacillin therapy.50
AHA recommends 2 g every 4 hours for ≥6 weeks in conjunction with oral rifampin (300 mg every 8 hours for 6 weeks or longer) and IM or IV gentamicin (1 mg/kg every 8 hours during the first 2 weeks of oxacillin therapy).50 (See Staphylococci Resistant to penicillinase-resistant Penicillins under Cautions.)
2 g every 4 hours.73
Modification of dosage generally is unnecessary in patients with renal impairment;18 53 56 some clinicians suggest that the lower range of the usual dosage (1 g IM or IV every 4–6 hours) be used in adults with Clcr <10 mL/minute.22 28 54 68
Hypersensitivity to any penicillin.1 58 64
Serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, reported with penicillins.1 58 64 Anaphylaxis occurs most frequently with parenteral penicillins but has occurred with oral penicillins.1 58 64
Prior to initiation of therapy, make careful inquiry regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other drugs.1 58 64 Partial cross-allergenicity occurs among penicillins and other β-lactam antibiotics including cephalosporins and cephamycins.1 33 34 42 43
If a severe hypersensitivity reaction occurs, discontinue immediately and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, maintenance of an adequate airway and oxygen).1 58 64
Possible emergence and overgrowth of nonsusceptible organisms.1 Careful observation of the patient is essential.1 Institute appropriate therapy if superinfection occurs.1
Treatment with anti-infectives may permit overgrowth of clostridia.1 Consider Clostridium difficile-associated diarrhea and colitis (antibiotic-associated pseudomembranous colitis) if diarrhea develops and manage accordingly.1
Some mild cases of C. difficile-asssociated diarrhea and colitis may respond to discontinuance alone.1 a Manage moderate to severe cases with fluid, electrolyte, and protein supplementation; appropriate anti-infective therapy (e.g., oral metronidazole or vancomycin) recommended if colitis is severe.1 a
Periodically assess organ system functions, including renal, hepatic, and hematopoietic, during prolonged therapy.1
Perform urinalysis and determine serum creatinine and BUN concentrations prior to and periodically during therapy.1 58 64
To monitor for hepatotoxicity, determine AST and ALT concentrations prior to and periodically during therapy.1 58 64
Because adverse hematologic effects have occurred with penicillinase-resistant penicillins, total and differential WBC counts should be performed prior to and 1–3 times weekly during therapy.40 41 58 64
To reduce development of drug-resistant bacteria and maintain effectiveness of oxacillin and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.
When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing1 In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.1
Consider that staphylococci resistant to penicillinase-resistant penicillins (referred to as oxacillin-resistant [methicillin-resistant] staphylococci) are being reported with increasing frequency.a
If oxacillin used empirically for treatment of any infection suspected of being caused by susceptible staphylococci, the drug should be discontinued and appropriate anti-infective therapy substituted if the infection is found to be caused by any organism other than penicillinase-producing staphylococci susceptible to penicillinase-resistant penicillins.1 If staphylococci resistant to penicillinase-resistant penicillins (oxacillin-resistant [methicillin-resistant] staphylococci) are prevalent in the hospital or community, empiric therapy of suspected staphylococcal infections should include another appropriate anti-infective (e.g., vancomycin).a
In treatment of endocarditis, consider that coagulase-negative staphylococci causing prosthetic valve endocarditis usually are resistant to penicillinase-resistant penicillins (especially when endocarditis develops within 1 year after surgery).50 Therefore, coagulase-negative staphylococci involved in prosthetic valve endocarditis should be assumed to be resistant to penicillinase-resistant penicillins unless results of in vitro testing indicate that the isolates are susceptible to the drugs.50
Each 1 g of oxacillin sodium powder for injection contains approximately 2.5 mEq of sodium and is buffered with 20 mg of dibasic sodium phosphate.1
Category B.1
Distributed into milk.58 63 Use with caution.58 63
Elimination of penicillins is delayed in neonates because of immature mechanisms for renal excretion; abnormally high serum concentrations may occur in this age group.58 63
If used in neonates, monitor closely for clinical and laboratory evidence of toxic or adverse effects, determine serum oxacillin concentrations frequently, and make appropriate reductions in dosage and frequency of administration when indicated.1 58 63
Hypersensitivity reactions; local reactions (phlebitis, thrombophlebitis); renal, hepatic, or nervous system effects with high dosage.a
Drug | Interaction | Comments |
|---|---|---|
Aminoglycosides | In vitro evidence of synergistic antibacterial effects against penicillinase-producing and nonpenicillinase-producing S. aureusa | |
Anticoagulants, oral (warfarin) | Possible decreased hypothrombinemic effect reported with other penicillinase-resistant penicillins (dicloxacillin, nafcillin)a | Monitor PT and adjust anticoagulant dosage if indicateda |
Cyclosporine | Decreased cyclosporine concentrations reported with some other penicillinase-resistant penicillins (e.g., nafcillin)a | |
Probenecid | Decreased renal tubular secretion of penicillinase-resistant penicillins and increased and prolonged plasma concentrationsa | |
Rifampin | In vitro evidence of indifference or synergism against S. aureus with low oxacillin concentrations and antagonism with high oxacillin concentrationsa Possible delay or prevention of emergence of rifampin-resistant S. aureusa | |
Tetracyclines | Possible antagonisma | Concomitant use not recommendeda |
Rapidly absorbed from IM injection sites;1 14 29 30 31 peak serum concentrations generally attained within 30 minutes.1 14 31
Distributed into synovial,5 24 pleural,1 5 pericardial,10 and ascitic fluids.10 Also distributed into bone,10 16 17 24 55 lungs,62 sputum,5 and bile.1 5 31
Only low concentrations attained in CSF.1 10 31
Crosses the placenta5 31 and is distributed into milk.1 5 31
89–94% bound to serum proteins.4 15 19 20 70
Partially metabolized to active and inactive metabolites.10 23 27
Approximately 49% of a dose is hydrolyzed to penicilloic acids which are microbiologically inactive;23 also hydroxylated to a small extent to a microbiologically active metabolite which appears to be slightly less active than oxacillin.27
Oxacillin and its metabolites rapidly eliminated in urine principally by tubular secretion and glomerular filtration.1 5 10 27 70
Following IM administration, 40–70% of the dose is excreted in urine as unchanged drug and active metabolites within 6 hours.31
Adults with normal renal function: 0.3–0.8 hours.1 7 10 15 21 22 45
Children 1 week to 2 years of age: 0.9–1.8 hours.26
Neonates: 1.6 hours in those 8–15 days of age and 1.2 hours in those 20–21 days of age.70
Patients with renal impairment: serum half-life slightly prolonged.7 15 18 28 45 Serum half-life may be 0.5–2 hours in patients with Clcr <10 mL/minute per 1.73 m2.7 15 18 45
15–30°C.68
Solutions reconstituted from ADD-Vantage vials using 0.9% sodium chloride injection or 5% dextrose injection are stable at room temperature for 4 days or 6 hours, respectively.63
IM solutions containing 167 mg/mL (250 mg/1.5 mL) prepared using sterile water for injection are stable for 3 days at room temperature or 7 days when refrigerated.1
≤ -20° C.64 Thawed solutions of the commercial frozen injection stable for 48 hours at room temperature (25°C) or 21 days at 5°C.64 65
Do not refreeze after thawing.64
For information on systemic interactions resulting from concomitant use, see Interactions.
Compatible |
|---|
Amino acids 4.25%, dextrose 25% |
Dextran 70 6% in dextrose 5% |
Dextran 40 10% in dextrose 5% |
Dextrose 5% in Ringer’s injection, lactated |
Dextrose 10% in water |
Hetastarch 6% in sodium chloride 0.9% |
Ringer’s injection, lactated |
Variable |
Dextrose 5% in sodium chloride 0.9% |
Dextrose 5% in water |
Sodium chloride 0.9% |
Compatible |
|---|
Chloramphenicol sodium succinate |
Dopamine HCl |
Potassium chloride |
Incompatible |
Cytarabine |
Variable |
Amikacin sulfate |
Verapamil HCl |
Compatible |
|---|
Acyclovir sodium |
Cyclophosphamide |
Diltiazem HCl |
Doxapram HCl |
Famotidine |
Fluconazole |
Foscarnet sodium |
Heparin sodium |
Hydrocortisone sodium succinate |
Hydromorphone HCl |
Labetalol HCl |
Levofloxacin |
Magnesium sulfate |
Meperidine HCl |
Methotrexate sodium |
Milrinone lactate |
Morphine sulfate |
Perphenazine |
Potassium chloride |
Tacrolimus |
Vitamin B complex with C |
Zidovudine |
Incompatible |
Sodium bicarbonate |
Verapamil HCl |
Based on spectrum of activity, classified as a penicillinase-resistant penicillin.4 5 9 10 46 58 70 64
Usually bactericidal.1
Like other β-lactam antibiotics, antibacterial activity results from inhibition of bacterial cell wall synthesis.1
Spectrum of activity includes many gram-positive aerobic cocci, some gram-positive bacilli, and a few gram-negative aerobic cocci; generally inactive against gram-negative bacilli and anaerobic bacteria.a Inactive against mycobacteria, Mycoplasma, Rickettsia, fungi, and viruses.a
Gram-positive aerobes: active in vitro against penicillinase-producing and nonpenicillinase-producing Staphylococcus aureus and S. epidermidis, S. pyogenes (group A β-hemolytic streptococci), S. agalactiae (group B streptococci), groups C and G streptococci, S. pneumoniae, and some viridans streptococci.a Enterococci (including E. faecalis) usually are resistant.a
Like other penicillinase-resistant penicillins, oxacillin is resistant to inactivation by staphylococcal penicillinases and is active against many penicillinase-producing strains of S. aureus and S. epidermidis resistant to natural penicillins, aminopenicillins, or extended-spectrum penicillins.9 11 58 70
Staphylococci resistant to penicillinase-resistant penicillins (referred to as oxacillin-resistant [methicillin-resistant] staphylococci) are being reported with increasing frequency.a Complete cross-resistance occurs among the penicillinase-resistant penicillins (dicloxacillin, nafcillin, oxacillin).a
Importance of discontinuing oxacillin and notifying clinician if evidence of hypersensitivity occurs.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1
Importance of women informing clinician if they are or plan to become pregnant or plan to breast-feed.1
Importance of advising patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Parenteral | For injection | 1 g (of oxacillin) | Oxacillin Sodium for Injection | Sandoz |
2 g (of oxacillin) | Oxacillin Sodium for Injection | Sandoz | ||
10 g (of oxacillin) pharmacy bulk package | Oxacillin Sodium for Injection | Sandoz | ||
For injection, for IV infusion | 1 g (of oxacillin) | Oxacillin Sodium ADD-Vantage | Sandoz | |
2 g (of oxacillin) | Oxacillin Sodium ADD-Vantage | Sandoz |
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Parenteral | Injection (frozen), for IV infusion | 20 mg (of oxacillin) per mL (1 g) in 3% Dextrose | Oxacillin Sodium in Iso-osmotic Dextrose Injection | Baxter |
40 mg (of oxacillin) per mL (2 g) in 0.6% Dextrose | Oxacillin Sodium in Iso-osmotic Dextrose Injection | Baxter |
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions September 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
1. Apothecon. Oxacillin sodium for injection for intramuscular or intravenous injection prescribing information. Princeton, NJ; 2001 Jan.
2. Apothecon. Oxacillin sodium for injection, USP pharmacy bulk package prescribing information. Princeton, NJ; 1998 Mar.
3. Apothecon. Oxacillin sodium for oral solution, USP prescribing information. Princeton, NJ; 1998 Mar.
4. Rolinson GN, Sutherland R. Semisynthetic penicillins. Adv Pharmacol Chemother. 1973; 11:152-220.
5. Marcy SM, Klein JO. The isoxazolyl penicillins: oxacillin, cloxacillin, and dicloxacillin. Med Clin North Am. 1970; 52:1127-43.
6. Barza M. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 2: penicillins. Am J Hosp Pharm. 1977; 34:57-67. [PubMed 318800]
7. Bergan T. Penicillins. In: Schonfeld H, ed. Antibiotics and chemotherapy. Vol 25. Basel: S. Karger; 1978:1-122.
8. Trissel LA. Handbook on injectable drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc; 2005:1144-1149.
9. Selwyn S. The mechanisms and range of activity of penicillins and cephalosporins. In: Selwyn S, ed. The beta-lactam antibiotics: penicillins and cephalosporins in perspective. London: Hodder and Stoughton; 1980:56-90.
10. Neu HC. Antistaphylococcal penicillins. Med Clin North Am. 1982; 66:51-60. [PubMed 7038340]
11. Cherubin CE, Corrado ML, Sierra MF. Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and n-formimidoyl thienamycin. Antimicrob Agents Chemother. 1981; 20:553-5. [IDIS 139345] [PubMed 6282200]
12. McAllister TA. Piperacillin against clinical isolates: antimicrobial profile and clinical role. J Antimicrob Chemother. 1982; 9(Suppl B):75-84. [PubMed 6460736]
13. Hammerstrom CF, Cox F, McHenry MC et al. Clinical, laboratory, and pharmacological studies of dicloxacillin. Antimicrob Agents Chemother. 1966:69-74.
14. Kirby WM, Rosenfeld LS, Brodie J. Oxacillin: laboratory and clinical evaluation. JAMA. 1962; 181:739-44. [PubMed 14456243]
15. Barza M, Weinstein L. Pharmacokinetics of the penicillins in man. Clin Pharmacokinet. 1976; 1:297-308. [PubMed 797501]
16. Tetzlaff TR, Howard JB, McCracken GH et al. Antibiotic concentrations in pus and bone in children with osteomyelitis. J Pediatr. 1978; 92:135-40. [IDIS 172809] [PubMed 619056]
17. Kolczun MC, Nelson CL, McHenry MC et al. Antibiotic concentrations in human bone. J Bone Joint Surg. 1974; 56A:305-9.
18. Ruedy J. The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease. Can Med Assoc J. 1966; 94:257-61. [PubMed 5903164]
19. Kunin CM. Clinical pharmacology of the new penicillins: the importance of serum protein binding in determining antimicrobial activity and concentrations in serum. Clin Pharmacol Ther. 1966; 7:166-79. [PubMed 4956690]
20. Kunin CM. Clinical significance of protein binding of the penicillins. Ann NY Acad Sci. 1967; 145:282-90. [PubMed 4998178]
21. Selwyn S. Applied pharmacology, adverse effects and drug interactions. In: Selwyn S, ed. The beta-lactam antibiotics: penicillins and cephalosporins in perspective. London: Hodder and Stoughton; 1980:91-126.
22. Giusti DL. A review of the clinical use of antimicrobial agents in patients with renal and hepatic insufficiency: the penicillins. Drug Intell Clin Pharm. 1973; 7:62-74.
23. Cole M, Kening MD, Hewitt VA. Metabolism of penicillins to penicilloic acids and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption. Antimicrob Agents Chemother. 1973; 3:463-8. [PubMed 4364176]
24. Fitzgerald RH, Kelly PJ, Snyder RJ et al. Penetration of methicillin, oxacillin, and cephalothin into bone and synovial tissue. Antimicrob Agents Chemother. 1978; 14:723-6. [IDIS 176044] [PubMed 727762]
25. Bass JW, Bruhn FW, Merritt WT et al. Comparison of oral penicillinase-resistant penicillins: contrasts between agents and assays. South Med J. 1982; 75:408-10. [IDIS 150080] [PubMed 7041278]
26. Burckart GJ, Evans WE, Whitington GL. Comparison of antibiotic serum concentrations after intramuscular oxacillin and oral cloxacillin in children. Am J Hosp Pharm. 1978; 35:1380-2. [PubMed 707507]
27. Thijssen HH, Mattie H. Active metabolites of isoxazolylpenicillins in humans. Antimicrob Agents Chemother. 1976; 10:441-6. [PubMed 825029]
28. Bulger RJ, Lindholm DD, Murray JS et al. Effect of uremia on methicillin and oxacillin blood levels. JAMA. 1964; 187:83-6.
29. Rutenburg AM, Greenberg HL. Oxacillin in staphylococcal infections: clinical evaluation of oral and parenteral administration. JAMA. 1964; 187:127-32.
30. Gravenkempter CF, Sweedler DR, Brodie JL et al. Cloxacillin: comparison of oral and parenteral forms with oxacillin and methicillin. Antimicrob Agents Chemother. 1964:237-49.
31. Prigot A, Froix CJ, Rubin E. Absorption, diffusion, and excretion of a new penicillin, oxacillin. Antimicrob Agents Chemother. 1962:402-10.
32. Bunn PA, Amrerg J. Initial clinical and laboratory experiences with methyl phenyl isoxazolyl penicillin (P-12). NY State J Med. 1961; 61:4158-62.
33. Idsoe O, Guthe T, Willcox RR et al. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ. 1968; 38:159-88. [PubMed 5302296]
34. Erffmeyer JE. Adverse reactions to penicillin. Ann Allergy. 1981; 47:288-300. [PubMed 6171185]
35. Dismukes WE. Oxacillin-induced hepatic dysfunction. JAMA. 1973; 226:861-3. [PubMed 4800332]
36. Onorato IM, Axelrod JL. Hepatitis from intravenous high-dose oxacillin therapy: findings in an adult inpatient population. Ann Intern Med. 1978; 89:497-500. [PubMed 697229]
37. Goldstein LI, Granoff M, Waisman J. Hepatic injury due to oxacillin administration. Am J Gastroenterol. 1978; 70:171-4. [IDIS 115295] [PubMed 717369]
38. Pollack AA, Berger SA, Simberkoff MS et al. Hepatitis associated with high-dose oxacillin therapy. Arch Intern Med. 1978; 138:915-7. [PubMed 646563]
39. Bruckstein AH, Attia AA. Oxacillin hepatitis: two patients with liver biopsy, and review of the literature. Am J Med. 1978; 64:519-22. [PubMed 637061]
40. Carpenter J. Neutropenia induced by semisynthetic penicillin. South Med J. 1980; 73:745-7. [IDIS 128169] [PubMed 7394597]
41. Homayouni H, Gross PA, Setia U et al. Leukopenia due to penicillin and cephalosporin homologues. Arch Intern Med. 1979; 139:827-8. [PubMed 454076]
42. Isbister JP. Penicillin allergy: a review of the immunological and clinical aspects. Med J Aust. 1971; 1:1067-74. [PubMed 4398272]
43. Sullivan TJ, Wedner HJ, Shatz GS et al. Skin testing to detect penicillin allergy. J Allergy Clin Immunol. 1981; 68:171-80. [IDIS 140792] [PubMed 6267115]
44. Havener WH. Ocular pharmacology. 4th ed. St. Louis: The CV Mosby Company; 1978:144-58.
45. Kind AC, Tupasi TE, Standiford HC et al. Mechanisms responsible for plasma levels of nafcillin lower than those of oxacillin. Arch Intern Med. 1970; 125:685-90. [PubMed 5437893]
46. Chambers HF. Penicillins. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000: 261-74.
47. Eichenwald HF, McCracken GH. Antimicrobial therapy in infants and children. Part I. Review of antimicrobial agents. J Pediatr. 1978; 93:336-56.
48. Parker RH, Fossieck BE. Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis. Ann Intern Med. 1980; 93:832-4. [IDIS 125287] [PubMed 7447189]
49. Armstrong EP, Rush DR. Treatment of osteomyelitis. Clin Pharm. 1983; 2:213-24. [IDIS 170639] [PubMed 6349907]
50. Wilson WR, Karchmer AW, Dajani AS et al and the Committee on Rheumatic Fever et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA. 1995; 274:1706-13. [IDIS 356429] [PubMed 7474277]
51. Dunkle LM, Brock N. Long-term follow-up of ambulatory management of osteomyelitis. Clin Pediatr. 1982; 21:650-5.
52. Kaplan SL, Mason EO, Feigin RD. Clindamycin versus nafcillin or methicillin in the treatment of Staphylococcus aureus osteomyelitis in children. South Med J. 1982; 75:138-42. [IDIS 145829] [PubMed 7036354]
53. Cheigh JS. Drug administration in renal failure. Am J Med. 1977; 62:555-63. [PubMed 851131]
54. Appel GB, Neu HC. The nephrotoxicity of antimicrobial agents (first of three parts). N Engl J Med. 1977; 296:663-70. [PubMed 402574]
55. Waldvogel FA, Vasey H. Osteomyelitis: the past decade. N Engl J Med. 1980; 303:360-70. [IDIS 119618] [PubMed 6993944]
56. Bennett WM, Aronoff GR, Morrison G et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis. 1983; 3:155-93. [PubMed 6356890]
57. McCracken GH, Eikenwald HF. Antimicrobial therapy in infants and children. Part II. Therapy of infectious conditions. J Pediatr. 1978; 93:357-77. [PubMed 357692]
58. US Food and Drug Administration. Penicillinase-resistant penicillin human prescription drugs class labeling guideline for professional labeling. [Notice of availability published in: Fed Regist. 1982; 47:41636.] Available from: Professional Labeling Branch, Division of Drug Advertising and Labeling, Food and Drug Administration, Rockville, MD.
59. Records RE. Human intraocular penetration of sodium oxacillin. Arch Ophthalmol. 1967; 77:693-5. [PubMed 6022741]
60. Records RE, Ellis PP. The intraocular penetration of ampicillin, methicillin, and oxacillin. Am J Ophthalmol. 1967; 64:135-43. [IDIS 4774] [PubMed 6028624]
61. Matsuda S. Transfer of antibiotics into maternal milk. Biol Res Pregnancy. 1984; 5:57-60.
62. Kiss J, Farago E, Fabian E. Study of oxacillin levels in human serum and lung tissue. Ther Hung. 1974; 22:55-9. [PubMed 4214521]
63. Apothecon. Oxacillin for injection (for intravenous injection only) in ADD-Vantage drug delivery system prescribing information. Princeton, NJ; 2001 Jan.
64. Baxter. Oxacillin injection, USP in plastic container for int
